Biotech Values

[rfj1862]

Oh good just what we need, more MM therapeutics.

I sometimes get a little irritated by all the activity in MM. It's driven by an incredibly aggressive and active foundation with strong links to the pharmaceutical industry rather than any rational considerations, and it has sucked funding and pharma dollars out of many other worthy areas. MM is a rare disease but you wouldn't know it based on the number of therapeutics and activity in this space.

Count me out on investing in heme/onc period in fact.